Buprenorphine 5, 10 and 20?gh transdermal patch: A review of its use in the management of chronic non-malignant pain

This article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20?gh) buprenorphine transdermal patch (BuTrans®, Norspan®) in the management of chronic non-malignant pain, with a focus on European labelling for the drug. Buprenorphine is a sem...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2011

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/23870

Acceso en línea:

https://doi.org/10.2165/11208250-000000000-00000
https://repository.urosario.edu.co/handle/10336/23870

Palabra clave:

Atazanavir
Buprenorphine
Carbamazepine
Central depressant agent
Codeine
Cyclooxygenase 2 inhibitor
Diclofenac
Dihydrocodeine
Efavirenz
Halothane
Ibuprofen
Ketoconazole
Mu opiate receptor
Naloxone
Nonsteroid antiinflammatory agent
Norspan
Oxycodone
Paracetamol
Phenobarbital
Phenytoin
Rifampicin
Ritonavir
Tilidine
Tramadol
Unclassified drug
Application site pruritus
Application site reaction
Chronic pain
Clinical trial (topic)
Constipation
Controlled clinical trial (topic)
Crossover procedure
Disease registry
Disease severity
Dizziness
Double blind procedure
Drug blood level
Drug dosage form comparison
Drug dose titration
Drug efficacy
Drug elimination
Drug formulation
Drug interaction
Drug metabolism
Drug tolerance
Drug withdrawal
Embase
Erythema
Gastrointestinal disease
Headache
Hip osteoarthritis
Human
Knee osteoarthritis
Loading drug dose
Low back pain
Low drug dose
Nausea
Nonhuman
Pruritus
Publication
Randomized controlled trial (topic)
Respiration depression
Review
Somnolence
Transdermal patch
Vomiting
Xerostomia
Adis-drug-evaluations
Buprenorphine
Pain
Transdermal

Rights

License

Abierto (Texto Completo)